NasdaqGS:ELVNPharmaceuticals
Enliven Therapeutics (ELVN): Assessing Valuation as Updated Clinical Data Approaches for Lead CML Candidate
Enliven Therapeutics (ELVN) caught investor interest with plans to share updated results from its ENABLE Phase 1 trial of ELVN-001 in chronic myeloid leukemia at the upcoming ASH 2025 Annual Meeting. Early signals pointed to encouraging safety and efficacy.
See our latest analysis for Enliven Therapeutics.
After a surge of attention around its upcoming ASH conference data, Enliven Therapeutics has seen some dramatic swings, with a one-day share price return of 6.1%. This stands in contrast to...